Table 3 Univariable (UVA) and multivariable (MVA) Cox regression model for prediction of early biochemical recurrence for clinical benefit cohort

From: Prospective study to define the clinical utility and benefit of Decipher testing in men following prostatectomy

  

UVA

MVA

GC Subset

Variable

HR (95% CI)

P value

HR (95% CI)

P value

Low/intermediate risk

CAPRA-S

1.5 (0.5–2.7)

0.345

1.4 (0.0–1265.0)

0.449

 

Treated vs not treated

4.0 (0.0–75.0)

0.456

1.3 (0.0–84.3)

0.926

High risk

CAPRA-S

1.2 (0.8–1.8)

0.430

1.5 (0.9–2.3)

0.093

 

Treated vs not treated

0.2 (0.0–0.8)

0.030*

0.1 (0.0–0.6)

0.013*

  1. CAPRA-S Cancer of the Prostate Risk Assessment score, GC genomic classifiers, HR hazard ratio, MVA multivariable analysis, PSA prostate-specific antigen, UVA univariable analysis, 95% CI 95% confidence interval, *significant p-value
Back to article page